JAMA ophthalmology最新文献

{"title":"Real-World Heterogeneity of Postretraction Citations.","authors":"Yusuke Kameda, Koshi Ota","doi":"10.1001/jamaophthalmol.2026.3212","DOIUrl":"10.1001/jamaophthalmol.2026.3212","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"979"},"PeriodicalIF":10.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Data and Temporal Risk Concerns of Semaglutide and NAION.","authors":"Chun-Hsien Yu","doi":"10.1001/jamaophthalmol.2026.3445","DOIUrl":"10.1001/jamaophthalmol.2026.3445","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"980"},"PeriodicalIF":10.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Heterogeneity of Postretraction Citations-Reply.","authors":"Victor Bellanda, Suraj Bala, Danny A Mammo","doi":"10.1001/jamaophthalmol.2026.3215","DOIUrl":"10.1001/jamaophthalmol.2026.3215","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"979-980"},"PeriodicalIF":10.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remote Robotic Retinal Surgery-Opportunities and Costs.","authors":"Matthew P Simunovic, Dong An, Andrew A Chang","doi":"10.1001/jamaophthalmol.2026.3476","DOIUrl":"10.1001/jamaophthalmol.2026.3476","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"960-961"},"PeriodicalIF":10.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Error in Figure 1.","authors":"","doi":"10.1001/jamaophthalmol.2026.3525","DOIUrl":"10.1001/jamaophthalmol.2026.3525","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"981"},"PeriodicalIF":10.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease: The TEASE-1 Randomized Clinical Trial.","authors":"Christine N Kay, Leonide Saad, Gabrielle DeBartolomeo, Neil Bressler, Stephen H Tsang, Kimberly Stepien, Paul Bernstein, Byron L Lam, Ilyas Washington, Michael B Gorin","doi":"10.1001/jamaophthalmol.2026.3662","DOIUrl":"10.1001/jamaophthalmol.2026.3662","url":null,"abstract":"<p><strong>Importance: </strong>Stargardt disease (STGD) is the most common macular dystrophy, resulting in profound loss of vision. There is no approved treatment.</p><p><strong>Objective: </strong>To evaluate the safety and effects of oral gildeuretinol acetate on the growth of retinal atrophic lesions in individuals with STGD.</p><p><strong>Design, setting, and participants: </strong>TEASE-1 was a 2-year, multicenter, double-masked, placebo-controlled randomized clinical trial incorporating a crossover group and additional natural history (NH) cases selected prior to drafting the statistical analysis plan. The trial was conducted at 7 outpatient clinics in the US. Participants were aged 12 years or older, clinically diagnosed with STGD, with well-demarcated area(s) of significantly reduced autofluorescence, and supported with at least 1 ABCA4 disease-causing or likely disease-causing variant. The study was conducted between August 2015 and October 2019; data were analyzed between July and December 2020.</p><p><strong>Interventions: </strong>Participants were randomized 1.5:1.5:1:1 to daily oral gildeuretinol acetate, 14 mg; gildeuretinol acetate, 24 mg; or placebo for 24 months; or placebo for 12 months followed by gildeuretinol for 12 months.</p><p><strong>Main outcomes and measures: </strong>The primary efficacy end point was the growth rate of well-delineated and homogeneous areas of retinal atrophic lesions over 24 months of treatment on fundus autofluorescence imaging. Safety end points included treatment-emergent adverse events (AEs), serious AEs, and clinical laboratory assessments.</p><p><strong>Results: </strong>A total of 50 participants were randomized, and 54 NH cases included. The mean (range) age of randomized participants was 44.3 (18-60) years. Overall, 58 of 104 participants or cases (55.8%) were female. The growth rate of retinal atrophic lesions was 0.182 mm/y with gildeuretinol and 0.232 mm/y in the untreated group (placebo and NH), representing a mean difference of -0.050 mm/y (95% CI, -0.072 to -0.027; P < .001) and a 21.6% relative reduction. In a prespecified sensitivity analysis restricted to randomized participants, the growth rate was 0.206 mm/y with gildeuretinol and 0.242 mm/y with placebo, representing a mean difference of -0.036 mm/y (95% CI, -0.062 to -0.009; P = .008) and a 14.9% relative reduction. The majority of AEs were mild or moderate and equally distributed between groups. No treatment-related serious AEs, clinically significant liver function abnormalities, or participant-reported night blindness or dark adaption difficulties occurred.</p><p><strong>Conclusions and relevance: </strong>In the TEASE-1 randomized clinical trial, the primary efficacy end point of retinal atrophic lesion growth from 6 to 24 months was 0.05 mm/y greater on average in the untreated group (placebo and NH) than the gildeuretinol acetate group. Further research is needed to determine the clinical relevance of this end point.</p><","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"944-952"},"PeriodicalIF":10.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13543036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acetazolamide for Retinoschisis in Branchio-Oculo-Facial Syndrome","authors":"Mihaela Chitoroaga, Daniela Gallo Castro, Aude Ambresin","doi":"10.1001/jamaophthalmol.2026.4207","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2026.4207","url":null,"abstract":"This case report discusses a patient with branchio-oculo-facial syndrome and bilateral optic nerve coloboma, with progressive retinoschisis disproportionate to coloboma extent and showing marked improvement after oral acetazolamide.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"66 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149083864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence for Diabetic Retinopathy.","authors":"Jennifer I Lim, Theodore Leng","doi":"10.1001/jamaophthalmol.2026.3479","DOIUrl":"10.1001/jamaophthalmol.2026.3479","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":"887-888"},"PeriodicalIF":10.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ten-Year Update of a Global Survey of Corneal Transplant and Eye Banking.","authors":"Oliver Dorado Cortez, Sylvain Poinard, Philippe Gain, Vito Romano, Serge Resnikoff, Gilles Thuret","doi":"10.1001/jamaophthalmol.2026.4147","DOIUrl":"10.1001/jamaophthalmol.2026.4147","url":null,"abstract":"<p><strong>Importance: </strong>Corneal transplant (CT) is the most frequent type of tissue transplant worldwide. A decade after the first global survey quantified a severe supply-demand imbalance, an updated analysis is needed to test whether progress has been equitable.</p><p><strong>Objective: </strong>To describe global CT and corneal procurement (CP) activity in 2022, compare findings with 2012, and characterize supply and demand by country income group.</p><p><strong>Design, setting, and participants: </strong>This global cross-sectional epidemiological study was conducted from December 2023 to December 2024. Data were obtained from a systematic literature review covering January 2018 to December 2024 and national or international eye banking registries. The 7-category supply-demand classification used in the 2012 survey was reapplied, with additional stratification by World Bank fiscal year 2023 country income group.</p><p><strong>Main outcomes and measures: </strong>The primary outcomes were country-level numbers and rates per million population of CTs and CPs, country income group distributions, and prevalence-based supply-demand ratios.</p><p><strong>Results: </strong>This study included 122 countries representing 89.5% of the world population. A total of 214 299 CTs were performed in 122 countries in 2022, a 16.1% increase from 184 576 in 2012. A total of 312 349 corneas were procured in 70 countries, a 10.2% increase outpaced by approximately 12% population growth, yielding a declining per capita procurement rate. The median (IQR) CT rate was 13.8 (5.0-43.4) per million; median (IQR) CP rate across procuring countries was 23.3 (7.2-69.4) per million. Median (IQR) CT rates were 43.1 (21.4-66.3) per million in high-income countries, 11.2 (6.0-22.6) per million in upper-middle-income countries, 4.4 (1.8-14.0) per million in lower-middle-income countries, and 0.4 (0.3-3.4) per million in low-income countries. Countries at or above the 2012 global median CT rate performed 89.7% of 2022 global CT activity while accounting for 44.1% of the cohort population. The prevalence-based supply-demand ratio was approximately 1:26 for bilateral corneal vision impairment and 1:55 when unilateral cases were included.</p><p><strong>Conclusions and relevance: </strong>In this global cross-sectional epidemiological study, despite a moderate increase in CT volume from 2012 to 2022, the supply-demand gap remains severe, and inequity has not narrowed. Coordinated investment in eye banking infrastructure in middle-income countries is needed alongside alternative therapies.</p>","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":""},"PeriodicalIF":10.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13613233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149037775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Exposure to Potentially Bogus Ophthalmic Treatments.","authors":"Lee Jones, Nikki Heinze, Mariya Moosajee","doi":"10.1001/jamaophthalmol.2026.4121","DOIUrl":"10.1001/jamaophthalmol.2026.4121","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":""},"PeriodicalIF":10.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13613219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149038762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}